An experimental coronavirus vaccine developed by a group of researchers from Oxford University and the biopharmaceutical company AstraZeneca, has showed early positive results in human trials.
Coronavirus vaccine: Oxford University trials shows it creates double immunity against Covid-19
The promising preliminary results, published this Monday in the scientific journal, The Lancet, revealed that the vaccine, called AZD1222, is safe and produces a strong immune reaction.
The clinical trials, which involved over 1,000 people aged between 18 and 55, showed that the Oxford Covid-19 injection didn’t promt any extreme side effects and provoked two immune responses.
Firstly, it created a T-cell response within 14 days of receiving the vaccination. The vaccine generated white cells that can attack cells infected with SARS-CoV-2.
Secondly, it provoked an antibody response within 28 days of vaccination. This means that antibodies are able to neutralize the virus from infecting cells when initially contracted.
Professor Andrew Pollar, chief investigator of the Oxford Vaccine Group at Oxford University and co-author of this study, said: “We saw the strongest immune response in the 10 participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination.”
Oxford Covid-19 vaccine: What’s next?
Further research is needed. So, the next step of the process is to confirm that this Oxford Covid-19 vaccine can be effective to completely prevent coronavirus infection.
This will be tried during Phase III where 10,000 people in the UK, 5,000 in Brazil and 2,000 in South Africa will be tested and monitored.
Oxford University and AstraZeneca are joining forces to produce the vaccine on a large scale.
They have already committed to supply more than 2 billion doses of the vaccine globally.
The British Government has backed the project with £84 million investment to be used for the development and manufacture of the vaccine.
Alok Sharma, Britain’s Secretary of State for Business, said: “Today’s results are extremely encouraging, taking us one step closer to finding a successful vaccine to protect millions in the UK and across the world.
“The agility and speed with which the University of Oxford have been working is outstanding. I am very proud of what they have achieved so far.”
Esperanzadora noticia sobre en avance del desarrollo de esta Vacuna, todavía experimental, gracias a la Universidad de Oxford y AstraZeneca.
Por el contenido de la Noticia, veo que están arribando a la Fase III. Que bueno. Dios quiera que ya pronto pueda abrirse la producción comercial y sea aplicada a la mayoría de la población mundial.
SOLAMENTE OBSERVO QUE todas las pruebas están realizándose en personas MENORES de 56 años!
QUE SUCEDERÁ con el Segmento Poblacional mayor a 55 años, POR CIERTO EL MÁS SUCEPTIBLE y expuesto a una complicación pulmonar o de otro tipo.
Habrán pruebas para ese segmento de 56 años o más???
Hola Jose,
Sí, la siguiente fase es testear la vacuna que ya tienen para ver si realmente puede proteger contra la infección de SARS-CoV-2. Por ahora, ha tenido resultados bastante positivos en los primeros ensayos con humanos, pero tienen que seguir investigando y probando para encontrar así la definitiva.
Imagino que una vez den con ésta, irán probando en diferentes sectores de la población, incluyendo personas de todas las edades y con diferentes características.
Desde luego ya anima ver que van por buen camino y que la cosa está bastante avanzada 🙂
Saludos,
Thaïs
Interesante
Hola Carlos,
La verdad es que sí. A confiar en que pronto saquen la vacuna definitiva. Habrá que estar al tanto de los avances 🙂
Saludos,
Thaïs
Comments are closed.